Company: RPTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103764
Chunk: 63

Company: Repare Therapeutics Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 63
---
 for 2022, Dr. Koehler and Dr. Zinda, who we collectively refer to in this section, as applicable, as “Non-PEONEOs.”

| Year |     | SummaryCompensationTable Totalfor PEO($) |           |     | CompensationActually Paidto PEO($)(1) |            |   |     | AverageSummaryCompensationTable TotalforNon-PEONEOs($) |           |     | AverageCompensationActually PaidtoNon-PEONEOs(1) 
 ($)                                              |          |   |     | Value ofInitial Fixed$100InvestmentBased onShareholderReturn(2) 
 ($)                                                             |       |     | Net Loss(inthousands)($)(3) |         |   |
| 2024 |     |                                          | 2,368,837 |     |                                       | (1,634,270 | ) |     |                                                        | 1,210,231 |     |                                                  |   44,146 |   |     |                                                                 |  3.82 |     |                             | (84,689 | ) |
| 2023 |     |                                          | 4,991,804 |     |                                       | (1,573,992 | ) |     |                                                        | 2,010,970 |     |                                                  | (317,435 | ) |     |                                                                 | 21.98 |     |                             | (93,796 | ) |
| 2022 |     |                                          | 4,021,395 |     |                                       |    910,352 |   |     |                                                        | 1,851,269 |     |                                                  |  484,853 |   |     |                                                                 | 42.89 |     |                             | (29,047 | ) |

| (1) | CAP reflects the total compensation reported in the Summary Compensation Table for the applicable year, adjusted to include or exclude the amount shown in the table below for the NEOs. Grant date fair value represents the grant date fair value of equity-based awards granted in each year. Fair value adjustments reflect adjustments to the value of equity awards as calculated in accordance with the rules prescribed under Item 402(v) of RegulationS-Kand in accordance with FASB ASC Topic 718. |

| (2) | Our Total Shareholder Return (“TSR”) for each of the applicable fiscal years is calculated based on a fixed investment of $100 at the applicable measurement point on the same cumulative basis as is used in Item